A Kulkarni
Royal Orthopaedic Hospital
10 Papers
68 Citations
A Kulkarni is an academic researcher from Royal Orthopaedic Hospital. The author has contributed to research in topics: Medicine & Glaucoma. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis.
TL;DR: Investigating the survival of endoprosthetic reconstructions in the medium to long term in order to determine the factors associated with their failure is believed to justify the continued use ofendoprostheses for reconstruction following the excision of a bone tumor.
263
The results of endoprosthetic replacement for tumours of the distal humerus
TL;DR: In this article, ten patients underwent endoprosthetic replacement of the distal humerus for bone tumours over a period of 30 years, and the functional results showed a mean Toronto extremity salvage score of 73% of normal.
The results of endoprosthetic replacements for tumours of the distal humerus
A Kulkarni,F. Fiorenza,RJ Grimer,S.R. Carter,RM Tillman +4 more
- 01 Mar 2008
TL;DR: Endoprosthetic replacement of the distal humerus and elbow is a satisfactory method of treating these rare tumours and four patients died from their disease, all with the prosthesis functioning satisfactorily.
46
One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis
Alex J Tanner,Fadi Haddad,Julia A. Fajardo-Sánchez,Ethan Nguyen,K. X. Thong,Sarah Ah-Moye,N. Perl,M. Abu-Bakra,A Kulkarni,S. Trikha,Gerassimos Lascaratos,Miles Parnell,Obeda Kailani,Anthony J King,Pavi Agrawal,Richard Stead,K. Giannouladis,Ian A Rodrigues,Saurabh Goyal,Pirro G. Hysi,Sheng Lim,C. Yu-Wai-Man +21 more
TL;DR: The PreserFlo MicroShunt with MMC 0.4 mg/mL showed an overall success rate of 68.3% at 1 year, and led to significant IOP and medication reduction with a low rate of adverse effects.
Clinical outcomes and cost analysis of PreserFlo® versus trabeculectomy for glaucoma management in the United Kingdom.
Lauren Van Lancker,A. Saravanan,M. Abu-Bakra,Kyle Reid,Claudia Quijano,Saurabh Goyal,Ian A Rodrigues,Gerassimos Lascaratos,S. Trikha,Caroline H S Barwood,Emily Combe,A Kulkarni,Kin Sheng Lim,Sancy Low +13 more
TL;DR: In this article , a cost analysis of mitomycin-C-augmented PreserFlo MicroShunt versus trabeculectomy was performed in 3 teaching hospitals in the UK and showed a savings of £245 to £566 per eye.
17